Comparison · NCT01597973-deaths
Colistin and Placebo vs Colistin and a Carbapenem: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Colistin and Placebo vs Colistin and a Carbapenem: deaths from any cause. Trial comparisons, record NCT01597973-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01597973-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.426 | 0.364 | 0.491 | wilson | |
| Risk in group 2 | 0.373 | 0.313 | 0.437 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0533 | -0.0362 | 0.142 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.14 | 0.912 | 1.43 | log | |
| Odds ratio, group 1 over group 2 | 1.25 | 0.859 | 1.82 | log | |
| Number needed to harm, for one more death from any cause on Colistin and Placebo than on Colistin and a Carbapenem | 18.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Colistin and Placebo | colistin and placebo: colistin- loading dose standard, maintenance dosed based on patient's renal function placebo- mimic meropenem (blinded) | 98 | 230 | EG000 |
| Group 2 | Colistin and a Carbapenem | colistin and carbapenem: colistin standard loading dose, maintenance dose based on patient's renal function carbapenem- dose based on patient's renal function | 85 | 228 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
For AEs, the assessment period begins at the time of enrollment and continues until 48 hours after end of treatment, that is up to 16 days. (as 48 hours is total removal of colistin from the patient has occurred). All-Cause Mortality, the Primary Objective is assessed up to 30 days after enrollment.
Source ClinicalTrials.gov
Trial
- Title
- Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)
- NCT number
- NCT01597973
- Phases
- PHASE3
- Conditions
- Pneumonia, Blood Stream Infection
- Interventions
- colistin and meropenem, colistin and placebo
- Lead sponsor
- University of Michigan
- Results first posted
- 2021-11-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01597973?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01597973-deaths